Observed Signal · Sep 10, 2026 · Product Launch · Source: Adweek · Impact: 4/5 · Sentiment: Positive
DeepIntent launches agentic ad platform Cora for pharma marketing
DeepIntent, a healthcare-focused adtech firm, has launched Cora, an AI-powered agentic advertising platform designed for pharmaceutical marketers. The platform uses multiple AI agents to handle campaign planning, audience strategy, and media execution, including linear TV via a VideoAmp integration. Cora aims to speed up marketing workflows, with beta tests showing a 50% reduction in planning cycles and over 95% of clients reporting faster processes. This launch follows DeepIntent's majority stake sale to Vitruvian Partners, which provided $637 million to develop AI tools. The company targets the growing complexity of pharma marketing, especially for niche drugs targeting small patient populations. Cora is also powered by Helix, a data application providing aggregated healthcare data, including payer signals and drug coverage insights.
Major platform launch introducing agentic AI to healthcare advertising, a niche but high-value segment, with potential to reshape pharma marketing workflows.
Track DeepIntent Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- DeepIntent launched Cora, an agentic ad platform for pharma marketing.
- Cora uses AI agents for campaign planning, audience targeting, and execution.
- Cora integrates with VideoAmp for linear TV campaign execution.
- Beta tests showed a 50% reduction in marketing planning time and over 95% client satisfaction.
- The platform is powered by Helix data, including payer and drug coverage signals.
Connected Companies & Entities
5 Entities mapped“DeepIntent, which specializes in helping pharma brands like Bayer, AstraZeneca, and Johnson & Johnson buy online ads, is positioning Cora as...”
“DeepIntent, which specializes in helping pharma brands like Bayer, AstraZeneca, and Johnson & Johnson buy online ads...”
“DeepIntent, which specializes in helping pharma brands like Bayer, AstraZeneca, and Johnson & Johnson buy online ads...”
“Last year, the digital ad buying platform DeepIntent sold a majority stake to private equity firm Vitruvian Partners, and vowed to use the $...”
“It also can power execution of the media plan. In beta testing, the platform cut marketing planning time cycles by 50%, with over 95% of cli...”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
DeepIntent Launches Cora, the First Fully Agentic Marketing Platform for Healthcare
DeepIntent announced the launch of Cora, described as the first fully agentic marketing platform for healthcare, marking a significant product introduction.
Pharma advertisers adopt specialized ad tech
Pharmaceutical marketers are increasingly shifting ad dollars from traditional TV to digital channels and adopting specialized ad tech built for healthcare’s regulatory and privacy constraints. Industry data cited in the article forecasts healthcare and pharma digital ad spending at $26.2 billion versus $6.9 billion for traditional media, with social surpassing linear TV in 2025. Sources tell Digiday that niche vendors such as DeepIntent, Patient Point and Pulsepoint are winning share from legacy DSPs. DeepIntent, after a majority-stake sale to Vitruvian Partners for $637 million in late 2025, unveiled a healthcare-focused agentic AI product called Helix AI and new tools to buy premium live-streaming TV inventory, touting partnerships with major broadcasters and sports-rights holders. Agency and ad buyers say evolving FDA and state-level regulations are driving privacy‑forward targeting and measurement approaches.
Cori Clinical Raises €3.8M to Accelerate Clinical Trials
London-based Cori Clinical, a startup providing an AI-powered intelligence layer for clinical trials, has raised €3.8 million in a Seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures, and Bynd. The company plans to use the funds to expand delivery capacity, grow its team, and deepen regulatory and clinical intelligence in its platform. Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health. Founded in 2025 by Jorn Jansen Schoonhoven (CEO) and Patricio Fernández (CTO), Cori Clinical creates a 'living blueprint' for trials, integrating internal knowledge with external data from registries and regulatory bodies like FDA, MHRA, and EMA. The startup claims its approach could reduce average trial set-up costs by at least 33%. It already works with two of the top five global CROs and has customers like Erasmus MC.
Receive all future signals for DeepIntent & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.